Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
33.6M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
5.46M
-
Shares change
-
+4.37M
-
Total reported value, excl. options
-
$3.09M
-
Value change
-
+$2.35M
-
Number of buys
-
17
-
Number of sells
-
-10
-
Price
-
$0.57
Significant Holders of Calidi Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (CLDI) as of Q1 2025
41 filings reported holding CLDI - Calidi Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Calidi Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (CLDI) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.46M shares
of 33.6M outstanding shares and own 16.23% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (3.32M shares), BANK OF MONTREAL /CAN/ (490K shares), VANGUARD GROUP INC (353K shares), GEODE CAPITAL MANAGEMENT, LLC (252K shares), Belpointe Asset Management LLC (250K shares), HighTower Advisors, LLC (119K shares), CPR Investments Inc. (101K shares), Red Wave Investments LLC (80.8K shares), STATE STREET CORP (61.3K shares), and RS CRUM INC. (55.3K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.